Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease
Abstract Nemonoxacin is a novel non-fluorinated quinolone with strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare. This study was conducted to compare the efficacy of oral nemonoxacin with moxifloxacin in AECOPD outp...
Main Authors: | Weiwei Meng, Huihui Zeng, Zhiqi Zhao, Ruoyan Xiong, Yan Chen, Zhuo Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-44188-2 |
Similar Items
-
Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia
by: Zhao B, et al.
Published: (2020-07-01) -
COPD exacerbation phenotypes: The next frontier
by: Moran, A, et al.
Published: (2019) -
In vitro pharmacodynamics of nemonoxacin and other antimicrobial agents against Mycoplasma pneumoniae
by: Na Wang, et al.
Published: (2023-12-01) -
Are intravenous steroids better than oral steroids in treating COPD exacerbations in hospitalized patients? A systematic review and meta-analysis
by: Rabbia Siddiqi, et al.
Published: (2023-12-01) -
Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance
by: Jinyi Yuan, et al.
Published: (2022-12-01)